WHAT RESEARCHERS STUDY
Primary research interest.
- Growth-hormone and IGF-1 signalling
- Visceral-adipose-tissue outcomes
- HIV-associated lipodystrophy
- Metabolic and body-composition studies
NEW
GROWTH HORMONE RESEARCH · IP-TESA-10
Tesamorelin
GHRH signalling and visceral-adipose-tissue research.
EVIDENCE SNAPSHOT · Approved drug molecule for a narrow indication
Tesamorelin is a synthetic growth-hormone-releasing hormone analogue. An FDA-approved prescription formulation is indicated for reduction of excess abdominal fat in adults with HIV-associated lipodystrophy; that approval does not apply to research-grade catalog material.
10 mg / vial$100.00 CAD
FOR LABORATORY RESEARCH USE ONLYNot for human or animal consumption. No dosing or administration information is provided.
COMMUNITY DISCUSSION · ANECDOTAL
What people discuss online.
Online discussions often describe tesamorelin as a “visceral-fat” compound rather than a general appetite suppressant. Anecdotal body-composition claims frequently extend far beyond the approved indication.
Community reports can be affected by placebo effects, concurrent products, training, diet, selection bias and inaccurate product identity.
EVIDENCE LIMITS
What the page does not claim.
The approved prescription product has specific manufacturing, dosing, monitoring and safety requirements. Imperial catalog material is not EGRIFTA and is not intended for treatment.
SOURCES & FURTHER READING
Review the evidence directly.
Current FDA prescribing information ↗FDA approval review ↗Community discussion — Reddit ↗Related catalog materials
View full catalog →
METABOLIC RESEARCH
Retatrutide
Triple-receptor agonist research compound
10 mg / vial$128.00
